Arch Biopartners Inc.

OTCPK:ACHF.F Stock Report

Market Cap: US$86.9m

Arch Biopartners Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:ACHF.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
31 Dec 24BuyUS$4,847Richard MuruveIndividual3,700US$1.32
24 Dec 24BuyUS$2,631Richard MuruveIndividual2,100US$1.26
20 Dec 24BuyUS$7,611Richard MuruveIndividual6,300US$1.23
29 Nov 24SellUS$2,798Richard MuruveIndividual2,000US$1.40
25 Nov 24BuyUS$686Richard MuruveIndividual500US$1.39
24 Oct 24SellUS$7,438Richard MuruveIndividual5,000US$1.49
04 Oct 24SellUS$1,362Richard MuruveIndividual1,000US$1.36
27 Sep 24SellUS$7,818Richard MuruveIndividual6,000US$1.32
18 Sep 24SellUS$3,575Richard MuruveIndividual3,000US$1.19
10 Sep 24SellUS$993Richard MuruveIndividual900US$1.10
06 Sep 24SellUS$664Richard MuruveIndividual600US$1.11
21 Jun 24SellUS$125,422Andrew BishopIndividual100,000US$1.25
06 Jun 24BuyUS$1,213Richard MuruveIndividual1,000US$1.22
31 May 24BuyUS$2,687Richard MuruveIndividual2,200US$1.23
22 May 24BuyUS$109,709Richard MuruveIndividual85,714US$1.28
21 May 24SellUS$109,923Daniel MuruveIndividual85,714US$1.28
08 Mar 24SellUS$2,695Richard MuruveIndividual2,104US$1.28

Insider Trading Volume

Insider Buying: ACHF.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ACHF.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders14,884,72922.9%
General Public49,973,62377.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.4%.

Top Shareholders

Top 5 shareholders own 22.95% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15%
Richard Muruve
9,710,110US$13.0m0.02%no data
3.3%
Richard Rossman
2,140,000US$2.9m0%no data
3.16%
Daniel Muruve
2,047,619US$2.7m0%no data
1.2%
Andrew Bishop
780,000US$1.0m0%no data
0.32%
Claude Allary
207,000US$277.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 10:52
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arch Biopartners Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chelsea StellickiA Capital Markets
Rahul SarugaserRaymond James Ltd.